Faes Farma Overview

  • Year Founded
  • 1933

Year Founded

  • Status
  • Public

  • Employees
  • 1,761


  • Stock Symbol
  • FAE

Stock Symbol

  • Investments
  • 9

  • Share Price
  • $3.38
  • (As of Friday Closing)

Faes Farma General Information


Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Stock Exchange
Corporate Office
  • Avenida Autonomia, 10
  • 48940 Leioa
  • Spain
+34 901 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Faes Farma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.38 $3.40 $3.03 - $3.75 $1.05B 311M 181K $0.31

Faes Farma Financials Summary

In Thousands,
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,049,125 1,049,125 1,068,483 1,077,995
Revenue 488,198 488,198 461,307 471,213
EBITDA 131,530 131,530 126,906 130,545
Net Income 99,445 99,445 94,096 97,410
Total Assets 857,822 857,822 779,794 730,411
Total Debt 26,415 26,415 35,051 18,618
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Faes Farma Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Faes Farma‘s full profile, request access.

Request a free trial

Faes Farma Patents

Faes Farma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4326279-A1 Universal dosage regime of 25-hydroxy vitamin d3 Pending 22-Apr-2021 00000000
EP-4188339-A1 Decongestant drug delivery system Pending 30-Jul-2020 000000000
EP-3808335-A1 Compositions for topical administration Pending 15-Oct-2019 000000000 00
JP-2022532585-A Methods and intermediates for preparing eldecalcitol Active 13-May-2019 000000000 0
US-11591280-B2 Process and intermediates for the preparation of eldecalcitol Active 13-May-2019 C07C41/48 0
To view Faes Farma’s complete patent history, request access »

Faes Farma Executive Team (3)

Name Title Board Seat Contact Info
Mariano Ucar President
Valentin Unamunzaga Chief Financial Officer and Deputy General Director
Xavier Arnaud Director Corporate Business Development and M&A
To view Faes Farma’s complete executive team members history, request access »

Faes Farma Board Members (4)

Name Representing Role Since
0000000 00 0000000 Faes Farma Board Member 000 0000
0000000 00000000 Faes Farma Board Member 000 0000
00000 000000000 00 Faes Farma Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Faes Farma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Faes Farma Investments & Acquisitions (9)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NovoSci 23-Dec-2022 0000000000 Distributors (Healthcare)
Global Farma 08-Mar-2021 0000000000 0000 Pharmaceuticals
BCN Medical 30-Oct-2019 0000000000 000.00 Distributors/Wholesale
AT Capselos 23-Jul-2018 000000000 00.000 Multi-line Chemicals
Tecnologia & Vitaminas 30-Jun-2017 Merger/Acquisition 000.00 Industrial Supplies and Parts
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

Faes Farma Subsidiaries (4)

Company Name Industry Location Founded
NovoSci Distributors (Healthcare) Dubai, United Arab Emirates 2014
Initial Technical Foods Food Products Lanciego Alava, Spain 0000
Global Farma Pharmaceuticals Guatemala 0000
Tecnologia & Vitaminas Industrial Supplies and Parts Tarragona, Spain 0000
To view Faes Farma’s complete subsidiaries history, request access »

Faes Farma ESG

Risk Overview

Risk Rating

Updated December, 08, 2022

30.82 | High Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,173






00 of 909






00 of 444




To view Faes Farma’s complete esg history, request access »

Faes Farma FAQs

  • When was Faes Farma founded?

    Faes Farma was founded in 1933.

  • Where is Faes Farma headquartered?

    Faes Farma is headquartered in Leioa, Spain.

  • What is the size of Faes Farma?

    Faes Farma has 1,761 total employees.

  • What industry is Faes Farma in?

    Faes Farma’s primary industry is Pharmaceuticals.

  • Is Faes Farma a private or public company?

    Faes Farma is a Public company.

  • What is Faes Farma’s stock symbol?

    The ticker symbol for Faes Farma is FAE.

  • What is the current stock price of Faes Farma?

    As of 12-Apr-2024 the stock price of Faes Farma is $3.38.

  • What is the current market cap of Faes Farma?

    The current market capitalization of Faes Farma is $1.05B.

  • What is Faes Farma’s current revenue?

    The trailing twelve month revenue for Faes Farma is $488M.

  • What is Faes Farma’s annual earnings per share (EPS)?

    Faes Farma’s EPS for 12 months was $0.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »